Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application

Dai ChuanYun, Fu Ya, Chen ShaoCheng, Li Biao, Yao Bo, Liu WanHong, Zhu LiQing, Chen Nan, Chen Ji, Zhang Qiang.
Sci China Life Sci (2013), Vol. 56, pages 51-58

Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results

Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA.
J Clin Oncol (2013) Jan 22

Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours

Zucali PA, Simonelli M, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Naimo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A.
Br J Cancer (2013), Vol. 108, pages 58-63

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation

Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE.
Ann Oncol (2012) Oct 26.

Systemic TNFα Gene Therapy Synergizes With Liposomal Doxorubicine in the Treatment of Metastatic Cancer

Su B, Cengizeroglu A, Farkasova K, Viola JR, Anton M, Ellwart JW, Haase R, Wagner E, Ogris M.
Mol Ther (2012) Nov 13. doi: 10.1038/mt.2012.229.

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

Lorusso D, Scambia G, Amadio G, di Legge A, Pietragalla A, De Vincenzo R, Masciullo V, Di Stefano M, Mangili G, Citterio G, Mantori M, Lambiase A, Bordignon C.
Br J Cancer (2012), Vol.107, pages 37-42

Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells

Kamel M, Shouman S, El-Merzebany M, Kilic G, Veenstra T, Saeed M, Wagih M, Diaz-Arrastia C, Patel D, Salama S.
J Cancer (2012), Vol.3, pages 310-21

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies

Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C.
Ann Oncol (2011), Vol.22, pages 973-8

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C.
Br J Cancer (2010), Vol.103, pages 837-44

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C.
Eur J Cancer (2010), Vol.46, pages 2746-52

TNFalpha gene delivery therapy for solid tumors

Hernandez J, Cooper J, Babel N, Morton C, Rosemurgy AS.
Expert Opin Biol Ther (2010), Vol.10, pages 993-9

Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand

Chae SY, Kim TH, Park K, Jin CH, Son S, Lee S, Youn YS, Kim K, Jo DG, Kwon IC, Chen X, Lee KC.
Mol Cancer Ther. (2010), Vol.9, pages 1719-29

Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation

Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ 3rd, Kraft SL, Gustafson DL, Vail DM.
Clin Cancer Res (2010), Vol.16, pages 1498-508

Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor

Meany HJ, Seibel NL, Sun J, Finklestein JZ, Sato J, Kelleher J, Sondel P, Reaman G.
J Immunother (2008), Vol.31, pages 679-83

TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility

R. van Horssen, T.L.M. ten Hagen and A.M.M. Eggermont
The Oncologist (2006), Vol. 11 pages 397-408

Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window

H. Shibata, Y. Yoshioka, S. Ikemizu, K. Kobayashi, Y. Yamamoto, Y. Mukai, T. Okamoto, M. Taniai, M. Kawamura, Y. Abe, S. Nakagawa, T. Hayakawa, S. Nagata, Y. Yamagata, T. Mayumi, H. Kamada and Y. Tsutsumi
Clinical Cancer Research (2004), Vol. 10 pages 8293-8300

Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency

Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Nagata S, Yamagata Y, Mayumi T.
Biochem Biophys Res Commun. (2004), Vol.315, pages 808-14

Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: a novel polymer-conjugation technique with a reversible amino-protective reagent

S. Tsunoda, T. Ishikawa, Y. Yamamoto, H. Kamada, K. Koizumi, J. Matsui, Y. Tsutsumi, T. Hirano and T. Mayumi
Journal of Pharmacology and Experimental Therapeutics (1999), Vol. 290 pages 368-372

Molecular design of hybrid tumor necrosis factor-α III: polyethylene glycol-modified tumor necrosis factor-α has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation

Y. Tsutsumi, T. Kihira, S. Tsunoda, H. Kamada, S. Nakagawa, Y. Kaneda, T. Kanamori and T. Mayumi
Journal of Pharmacology and Experimental Therapeutics (1999), Vol. 278 pages 1006-1011

In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-α against tumor necrosis factor resistant tumors

Y. Tsutsumi, S. Tsunoda, Y. Kaneda, H. Kamada, T. Kihira, S. Nakagawa, Y. Yamamoto, Y. Horisawa and T. Mayumi
Japanese Journal of Cancer Research (1996), Vol. 87 pages 1078-1085

Molecular design of hybrid tumour necrosis factor α with polyethylene glycol increases its anti-tumour potency

Y. Tsutsumi, T. Kihira, S. Tsunoda, T. Kanamori, S. Nakagawa and T. Mayumi
British Journal of Cancer (1995), Vol. 71 pages 963-968

Intravenous administration of polyethylene glycol-modified tumor necrosis factor-α completely regressed solid tumor in Meth-A murine sarcoma model

Y. Tsutsumi, T. Kihira, S. Tsunoda, K. Kubo, M. Miyake, T. Kanamori, S. Nakagawa and T. Mayumi
Japanese Journal of Cancer Research (1994), Vol. 85 pages 1185-1188.

Chemical modification of natural human tumor necrosis factor-α with polyethylene glycol increases its anti-tumor potency

Y. Tsutsumi, T. Kihira, S. Yamamoto K. Kubo, S. Nakagawa, M. Miyake, Y. Horisawa, T. Kanamori, H. Ikegami and T, Mayumi
Japanese Journal of Cancer Research (1994), Vol. 85 pages 9-12

Tumour necrosis factor in man: clinical and biological observations

P. Selby, S. Hobbs, C. Viner, E. Jackson, A. Jones, D. Newell, A.H. Calvert, T. McElwain, K. Fearon and J. Humphreys
British Journal of Cancer (1987), Vol. 56 pages 803-808

Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice

K. Haranaka, N. Satomi and A. Sakurai
International Journal of Cancer (1984), Vol. 34 pages 263-267

An endotoxin-induced serum factor that causes necrosis of tumors

E.A. Carswell, L.J. Old, R.L. Kassel, S. Green, N. Fiore and B.D. Williamson
Proceedings of the National Academy of Sciences (1975), Vol. 72 pages 3666-3670